Log in

Relevant bibliographies by topics / Oncolytic Viral Therapy / Journal articles

To see the other types of publications on this topic, follow the link: Oncolytic Viral Therapy.

Journal articles on the topic 'Oncolytic Viral Therapy'

Author: Grafiati

Published: 3 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Oncolytic Viral Therapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Zurkiya, Omar, and Suvranu Ganguli. "Viral Oncolytic Therapy." Journal of Clinical Interventional Radiology ISVIR 01, no. 02 (2017): 096–99. http://dx.doi.org/10.1055/s-0037-1602389.

Full text

Abstract:

AbstractViral oncolysis broadly refers to the use of modified viruses to infect and subsequently lyse tumor cells. This concept arises from the observation that viral replication is itself effective in destroying tumor cells. This effect is then amplified by reinfection of adjacent tumor cells by the progeny virion released from lysed tumor cells. Herpes simplex virus 1 (HSV-1) has been the primary focus of current efforts in viral oncolysis. It is a double-stranded DNA virus that is a ubiquitous pathogen transmitted by direct mucosal contact. HSV-1 possesses several features well suited to vi

APA, Harvard, Vancouver, ISO, and other styles

2

Hackethal, Veronica. "Oncolytic Viral Therapy." Oncology Times 42, no. 11 (2020): 1–9. http://dx.doi.org/10.1097/01.cot.0000669692.29645.ac.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Karadimas, Thomas, Thien Huong Huynh, Chloe Chose, et al. "Oncolytic Viral Therapy in Osteosarcoma." Viruses 16, no. 7 (2024): 1139. http://dx.doi.org/10.3390/v16071139.

Full text

Abstract:

Primary bone malignancies, including osteosarcoma (OS), are rare but aggressive. Current OS treatment, involving surgical resection and chemotherapy, has improved survival for non-metastatic cases but remains ineffective for recurrent or metastatic OS. Oncolytic viral therapy (OVT) is a promising alternative, using naturally occurring or genetically modified viruses to selectively target and lyse cancer cells and induce a robust immune response against remaining OS cells. Various oncolytic viruses (OVs), such as adenovirus, herpes simplex virus, and measles virus, have demonstrated efficacy in

APA, Harvard, Vancouver, ISO, and other styles

4

Vengadaragava Chary, Krishnan, and Anish Bharatwaj. "ONCOLYTIC VIRAL THERAPY IN CANCER THERAPEUTICS." Asian Journal of Pharmaceutical and Clinical Research 10, no. 10 (2017): 96. http://dx.doi.org/10.22159/ajpcr.2017.v10i10.19265.

Full text

Abstract:

Objective: The aim of this study is to provide comprehensive information of oncolytic viral therapy, from the origin to present scenario.Methods: This observational study was conducted by the Department of Pharmacology, Saveetha Medical College, Chennai between July and December 2016. Date regarding ongoing oncolytic virotherapy trials was retrieved from clinical trial database, United States and Clinical trial registry forum, India. Tamilnogene approval details were obtained from the US-Food and Drug Administration approval new drug approval information.Results: Eleven ongoing trials in Phase

APA, Harvard, Vancouver, ISO, and other styles

5

Kim, Sang-In, Shyambabu Chaurasiya, Anthony K. Park, et al. "Vitamin D as a Primer for Oncolytic Viral Therapy in Colon Cancer Models." International Journal of Molecular Sciences 21, no. 19 (2020): 7326. http://dx.doi.org/10.3390/ijms21197326.

Full text

Abstract:

Oncolytic viroimmunotherapy is an exciting modality that can offer lasting anti-tumor immunity for aggressive malignancies like colon cancer. The impact of oncolytic viruses may be extended by combining them with agents to prime a tumor for viral susceptibility. This study investigates vitamin D analogue as an adjunct to oncolytic viral therapy for colon cancer. While vitamin D (VD) has historically been viewed as anti-viral, our in vitro investigations using human colon cancer cell lines showed that VD does not directly inhibit replication of recombinant chimeric poxvirus CF33. VD did restric

APA, Harvard, Vancouver, ISO, and other styles

6

Haddad, Dana, and Yuman Fong. "Molecular imaging of oncolytic viral therapy." Molecular Therapy - Oncolytics 1 (2014): 14007. http://dx.doi.org/10.1038/mto.2014.7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Parker, Jacqueline Nuss, David F. Bauer, James J. Cody, and James M. Markert. "Oncolytic viral therapy of malignant glioma." Neurotherapeutics 6, no. 3 (2009): 558–69. http://dx.doi.org/10.1016/j.nurt.2009.04.011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Advani, Sunil J., James J. Mezhir, Bernard Roizman, and Ralph R. Weichselbaum. "ReVOLT: radiation-enhanced viral oncolytic therapy." International Journal of Radiation Oncology*Biology*Physics 66, no. 3 (2006): 637–46. http://dx.doi.org/10.1016/j.ijrobp.2006.06.034.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Rahal, Ahmad, and Benjamin Musher. "Oncolytic viral therapy for pancreatic cancer." Journal of Surgical Oncology 116, no. 1 (2017): 94–103. http://dx.doi.org/10.1002/jso.24626.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Alvarez-Breckenridge, Christopher A., Jianhua Yu, Balveen Kaur, Michael A. Caligiuri, and E. Antonio Chiocca. "Deciphering the Multifaceted Relationship between Oncolytic Viruses and Natural Killer Cells." Advances in Virology 2012 (2012): 1–14. http://dx.doi.org/10.1155/2012/702839.

Full text

Abstract:

Despite active research in virotherapy, this apparently safe modality has not achieved widespread success. The immune response to viral infection appears to be an essential factor that determines the efficacy of oncolytic viral therapy. The challenge is determining whether the viral-elicited immune response is a hindrance or a tool for viral treatment. NK cells are a key component of innate immunity that mediates antiviral immunity while also coordinating tumor clearance. Various reports have suggested that the NK response to oncolytic viral therapy is a critical factor in premature viral clea

APA, Harvard, Vancouver, ISO, and other styles

11

Garg, Ayushi, Rohit Rao, Felicia Tejawinata, et al. "Advances in Oncolytic Viral Therapy in Melanoma: A Comprehensive Review." Vaccines 13, no. 7 (2025): 727. https://doi.org/10.3390/vaccines13070727.

Full text

Abstract:

Checkpoint inhibitor therapy revolutionized the treatment of patients with melanoma. However, in patients where melanoma exhibits resistance to checkpoint inhibitor therapy, the treatment options are limited. Oncolytic viruses are a unique form of immunotherapy that uses live viruses to infect and lyse tumor cells to release the elusive neoantigen picked up by the antigen-presenting cells, thus increasing the chances of an immune response against cancer. Coupled with checkpoint inhibitors, intratumoral injections of the oncolytic virus can help an enhanced immune response, especially in a tumo

APA, Harvard, Vancouver, ISO, and other styles

12

Phillips, Lynette, Joy Gumin, Shoudong Li, et al. "TMOD-16. A NOVEL ADENOVIRAL-PERMISSIVE, IMMUNOCOMPETENT HAMSTER GLIOMA MODEL TO EVALUATE ONCOLYTIC ADENOVIRAL THERAPY." Neuro-Oncology 22, Supplement_2 (2020): ii231. http://dx.doi.org/10.1093/neuonc/noaa215.967.

Full text

Abstract:

Abstract Oncolytic adenoviruses, including Delta-24-RGD, target tumors by direct tumor cell oncolysis and by activation of an anti-tumor immune response. Due to the species selectivity of oncolytic adenoviruses, there is currently no single preclinical animal model of glioma that supports viral replication, tumor oncolysis, and virus-mediated immune responses. To address this gap, we took advantage of the Syrian hamster to develop the first glioma model that is both adenovirus replication-permissive and immunocompetent. Hamster glioma stem-like cells (GSCs), transformed by forced expression of

APA, Harvard, Vancouver, ISO, and other styles

13

Tysome, James Russell, Ghassan Alusi, Nick Lemoine, and Yaohe Wang. "Oncolytic Vaccinia Virus Gene Therapy for HNSCC." Otolaryngology–Head and Neck Surgery 139, no. 2_suppl (2008): P92—P93. http://dx.doi.org/10.1016/j.otohns.2008.05.500.

Full text

Abstract:

Problem Oncolytic viral therapy a promising new strategy for the treatment of cancer and an oncolytic adenovirus was first licensed for head and neck squamous cell carcinoma (HNSCC). However, the outcomes of clinical trials with viral monotherapy have been disappointing. Oncolytic vaccinia virus represents an attractive alternative as its replication is less dependent than adenovirus on the genetic make-up of tumor cells and it has been used safely as the smallpox vaccine in millions of patients. Methods The potency and replication of vaccinia virus and adenovirus were compared in a panel of H

APA, Harvard, Vancouver, ISO, and other styles

14

Chumakov, P. M. "Could oncolytic viruses provide a breakthrough in oncology?" Вестник Российской академии наук 89, no. 5 (2019): 475–84. http://dx.doi.org/10.31857/s0869-5873895475-484.

Full text

Abstract:

Despite the long-term and intensive studies of the nature of cancer and the development of numerous anti-cancer drugs, the incidence of cancer is growing, and the five-year survival of cancer patients diagnosed at the advanced stages of the disease remains unacceptably low. The author examines the causes of the failures in cancer therapy, which are rooted in the very nature of malignant cells, as these cells can adapt and acquire resistance to almost any systemic therapy. In this regard, considerable hopes are associated with oncolytic viruses, which represent a distinct type of remedies capab

APA, Harvard, Vancouver, ISO, and other styles

15

Anelone, Anet J. N., María F. Villa-Tamayo, and Pablo S. Rivadeneira. "Oncolytic virus therapy benefits from control theory." Royal Society Open Science 7, no. 7 (2020): 200473. http://dx.doi.org/10.1098/rsos.200473.

Full text

Abstract:

Oncolytic virus therapy aims to eradicate tumours using viruses which only infect and destroy targeted tumour cells. It is urgent to improve understanding and outcomes of this promising cancer treatment because oncolytic virus therapy could provide sensible solutions for many patients with cancer. Recently, mathematical modelling of oncolytic virus therapy was used to study different treatment protocols for treating breast cancer cells with genetically engineered adenoviruses. Indeed, it is currently challenging to elucidate the number, the schedule, and the dosage of viral injections to achie

APA, Harvard, Vancouver, ISO, and other styles

16

Hromic-Jahjefendic, Altijana, and Kenneth Lundstrom. "Viral Vector-Based Melanoma Gene Therapy." Biomedicines 8, no. 3 (2020): 60. http://dx.doi.org/10.3390/biomedicines8030060.

Full text

Abstract:

Gene therapy applications of oncolytic viruses represent an attractive alternative for cancer treatment. A broad range of oncolytic viruses, including adenoviruses, adeno-associated viruses, alphaviruses, herpes simplex viruses, retroviruses, lentiviruses, rhabdoviruses, reoviruses, measles virus, Newcastle disease virus, picornaviruses and poxviruses, have been used in diverse preclinical and clinical studies for the treatment of various diseases, including colon, head-and-neck, prostate and breast cancer as well as squamous cell carcinoma and glioma. The majority of studies have focused on i

APA, Harvard, Vancouver, ISO, and other styles

17

Chaurasiya, Shyambabu, Yuman Fong, and Susanne G. Warner. "Optimizing Oncolytic Viral Design to Enhance Antitumor Efficacy: Progress and Challenges." Cancers 12, no. 6 (2020): 1699. http://dx.doi.org/10.3390/cancers12061699.

Full text

Abstract:

The field of oncolytic virotherapy has seen remarkable advancements in last two decades, leading to approval of the first oncolytic immuno-virotherapy, Talimogene Laherparepvec, for the treatment of melanoma. A plethora of preclinical and clinical studies have demonstrated excellent safety profiles of other oncolytic viruses. While oncolytic viruses show clinical promise in already immunogenic malignancies, response rates are inconsistent. Response rates are even less consistent in immunosuppressed tumor microenvironments like those found in liver, pancreas, and MSI-stable colon cancers. There

APA, Harvard, Vancouver, ISO, and other styles

18

Kong, Hao, Ruibo Zhao, Quan Zhang, et al. "Biosilicified oncolytic adenovirus for cancer viral gene therapy." Biomaterials Science 8, no. 19 (2020): 5317–28. http://dx.doi.org/10.1039/d0bm00681e.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Eager, R. M., and J. Nemunaitis. "Clinical development directions in oncolytic viral therapy." Cancer Gene Therapy 18, no. 5 (2011): 305–17. http://dx.doi.org/10.1038/cgt.2011.7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Slaney, Clare Y., and Phillip K. Darcy. "Releasing the Brake on Oncolytic Viral Therapy." Clinical Cancer Research 21, no. 24 (2015): 5417–19. http://dx.doi.org/10.1158/1078-0432.ccr-15-1769.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Huff, Amanda L., Phonphimon Wongthida, Timothy Kottke, et al. "APOBEC3 Mediates Resistance to Oncolytic Viral Therapy." Molecular Therapy - Oncolytics 11 (December 2018): 1–13. http://dx.doi.org/10.1016/j.omto.2018.08.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Man, Y. K. Stella, Constantia Pantelidou, Alfonso Blázquez-Moreno, et al. "Modifying oncolytic viral therapy for pancreatic cancer." Pancreatology 16, no. 3 (2016): S4. http://dx.doi.org/10.1016/j.pan.2016.04.017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

McConkey, David J. "RAIDDing ER Stress for Oncolytic Viral Therapy." Cancer Cell 20, no. 4 (2011): 416–18. http://dx.doi.org/10.1016/j.ccr.2011.10.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Yang, Haitang, Duo Xu, Yanyun Gao, Ralph A. Schmid, and Ren-Wang Peng. "Oncolytic Viral Therapy for Malignant Pleural Mesothelioma." Journal of Thoracic Oncology 15, no. 7 (2020): e111-e113. http://dx.doi.org/10.1016/j.jtho.2020.03.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Lesmana, Jevon Aaron, and Juandy Jo. "Future Application of Oncolytic Viruses for Cancer Treatment." Medicinus 10, no. 3 (2023): 130. http://dx.doi.org/10.19166/med.v10i3.7037.

Full text

Abstract:

<p>Cancer treatments have developed over the years. A particular improvement is the utilization of oncolytic viruses to treat cancers. Oncolytic viruses are one of the immunotherapeutic tools that potentially could provide good results and benefits to the patients. Oncolytic viruses could mediate antitumor effects. Indeed, the connection between viral infections and cancer treatment have been reported historically. It is known that oncolytic viruses prefer to infect cancer cells rather than normal cells, resulting in the presentation of tumor-associated antigens to the immune system, boo

APA, Harvard, Vancouver, ISO, and other styles

26

Klaan, N. K., L. P. Аkin’shina, and T. A. Pronina. "Oncolitical viruses in the therapy of malignant neoplastic diseases." Russian Journal of Biotherapy 17, no. 4 (2019): 6–19. http://dx.doi.org/10.17650/1726-9784-2018-17-4-6-19.

Full text

Abstract:

The main types of oncolytic viruses and the mechanisms of their action on the tumor cells are described in this review. Examples of optimization of the viral genome are given with a view to enhancing the oncolytic properties of the virus. The achievements in the field of development of antitumour agents based on oncolytic viruses and methods of their application in oncology are described.

APA, Harvard, Vancouver, ISO, and other styles

27

Patiño-García, Ana, Marta M. Alonso, and Jaime Gállego Pérez-Larraya. "Promises of oncolytic viral therapy for adult and children with brain glioma." Current Opinion in Oncology 35, no. 6 (2023): 529–35. http://dx.doi.org/10.1097/cco.0000000000000995.

Full text

Abstract:

Purpose of review The purpose of this review is to give an overview of early clinical studies addressing the safety and efficacy of oncolytic immunovirotherapy in adults and children with brain gliomas, and to highlight the extensive potential for the development of this therapeutic alternative. Recent findings The lack of curative treatments and poor prognosis of high-grade glioma patients warrants research on innovative therapeutic alternatives such as oncolytic immunovirotherapy. Engineered modified oncolytic viruses exert both a direct lytic effect on tumor cells and a specific antitumor i

APA, Harvard, Vancouver, ISO, and other styles

28

Cheng, Xing, Weijia Wang, Qi Xu, et al. "Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy." Journal of Virology 90, no. 11 (2016): 5343–52. http://dx.doi.org/10.1128/jvi.00136-16.

Full text

Abstract:

ABSTRACTClinical development of a mesogenic strain of Newcastle disease virus (NDV) as an oncolytic agent for cancer therapy has been hampered by its select agent status due to its pathogenicity in avian species. Using reverse genetics, we have generated a lead candidate oncolytic NDV based on the mesogenic NDV-73T strain that is no longer classified as a select agent for clinical development. This recombinant NDV has a modification at the fusion protein (F) cleavage site to reduce the efficiency of F protein cleavage and an insertion of a 198-nucleotide sequence into the HN-L intergenic regio

APA, Harvard, Vancouver, ISO, and other styles

29

Nettelbeck, Dirk M., Mathias F. Leber, Jennifer Altomonte, et al. "Virotherapy in Germany—Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies." Viruses 13, no. 8 (2021): 1420. http://dx.doi.org/10.3390/v13081420.

Full text

Abstract:

Virotherapy research involves the development, exploration, and application of oncolytic viruses that combine direct killing of cancer cells by viral infection, replication, and spread (oncolysis) with indirect killing by induction of anti-tumor immune responses. Oncolytic viruses can also be engineered to genetically deliver therapeutic proteins for direct or indirect cancer cell killing. In this review—as part of the special edition on “State-of-the-Art Viral Vector Gene Therapy in Germany”—the German community of virotherapists provides an overview of their recent research activities that c

APA, Harvard, Vancouver, ISO, and other styles

30

Vithanage, G. V. R. K., and Sophia R-J Jang. "Optimal Immunotherapy of Oncolytic Viruses and Adopted Cell Transfer in Cancer Treatment." WSEAS TRANSACTIONS ON BIOLOGY AND BIOMEDICINE 19 (June 7, 2022): 140–50. http://dx.doi.org/10.37394/23208.2022.19.15.

Full text

Abstract:

We investigate therapeutic effects of monotherapy of oncolytic viruses, of adopted cell transfer, as well as the two combined therapies over a short time treatment period by applying optimal control techniques. The goal is to minimize the number of susceptible tumor cells and the costs associated with the therapy over the treatment period. We verify that there exists an optimal control pair and derive the necessary conditions. The optimality system is solved numerically to provide optimal protocols under different scenarios with respect to initial tumor sizes and parameter values. Although the

APA, Harvard, Vancouver, ISO, and other styles

31

Bots, Selas T. F., and Rob C. Hoeben. "Non-Human Primate-Derived Adenoviruses for Future Use as Oncolytic Agents?" International Journal of Molecular Sciences 21, no. 14 (2020): 4821. http://dx.doi.org/10.3390/ijms21144821.

Full text

Abstract:

Non-human primate (NHP)-derived adenoviruses have formed a valuable alternative for the use of human adenoviruses in vaccine development and gene therapy strategies by virtue of the low seroprevalence of neutralizing immunity in the human population. The more recent use of several human adenoviruses as oncolytic agents has exhibited excellent safety profiles and firm evidence of clinical efficacy. This proffers the question whether NHP-derived adenoviruses could also be employed for viral oncolysis in human patients. While vaccine vectors are conventionally made as replication-defective vector

APA, Harvard, Vancouver, ISO, and other styles

32

Alwithenani, Akram, Rozanne Arulanandam, Boaz Wong, et al. "Tepilamide Fumarate as a Novel Potentiator of Virus-Based Therapy." Viruses 16, no. 6 (2024): 920. http://dx.doi.org/10.3390/v16060920.

Full text

Abstract:

Oncolytic virotherapy, using viruses such as vesicular stomatitis virus (VSVΔ51) and Herpes Simplex Virus-1 (HSV-1) to selectively attack cancer cells, faces challenges such as cellular resistance mediated by the interferon (IFN) response. Dimethyl fumarate (DMF) is used in the treatment of multiple sclerosis and psoriasis and is recognized for its anti-cancer properties and has been shown to enhance both VSVΔ51 and HSV-1 oncolytic activity. Tepilamide fumarate (TPF) is a DMF analog currently undergoing clinical trials for the treatment of moderate-to-severe plaque psoriasis. The aim of this s

APA, Harvard, Vancouver, ISO, and other styles

33

Schirrmacher, Volker. "Molecular Mechanisms of Anti-Neoplastic and Immune Stimulatory Properties of Oncolytic Newcastle Disease Virus." Biomedicines 10, no. 3 (2022): 562. http://dx.doi.org/10.3390/biomedicines10030562.

Full text

Abstract:

Oncolytic viruses represent interesting anti-cancer agents with high tumor selectivity and immune stimulatory potential. The present review provides an update of the molecular mechanisms of the anti-neoplastic and immune stimulatory properties of the avian paramyxovirus, Newcastle Disease Virus (NDV). The anti-neoplastic activities of NDV include (i) the endocytic targeting of the GTPase Rac1 in Ras-transformed human tumorigenic cells; (ii) the switch from cellular protein to viral protein synthesis and the induction of autophagy mediated by viral nucleoprotein NP; (iii) the virus replication

APA, Harvard, Vancouver, ISO, and other styles

34

Alvarez-Breckenridge, Christopher A., Bryan D. Choi, Carter M. Suryadevara, and E. Antonio Chiocca. "Potentiating oncolytic viral therapy through an understanding of the initial immune responses to oncolytic viral infection." Current Opinion in Virology 13 (August 2015): 25–32. http://dx.doi.org/10.1016/j.coviro.2015.03.015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Y, Pramod Kumar. "Vaccine Strain of Measles Virus: A Tool for Cancer Therapy." Virology & Immunology Journal 7, no. 1 (2023): 1–18. http://dx.doi.org/10.23880/vij-16000307.

Full text

Abstract:

Measles virus, the causative agent of measles, possesses a latently oncotropic character. This character enables the virus to infect, syntialize and lyse the cancer cells. The live attenuated strains, specially the Edmonston strain, recognize CD46 as their receptor. CD46 is overexpressed in adenocarcinoma cells. There is a basal level of expression of CD46 in all nucleated cells. The Edmonton vaccine strain has high affinity towards CD46 receptor but the wild stain has strong affinity towards CD150/ SLAM expressed on the lymphoid cells and epithelial nectin-4. This natural property of the live

APA, Harvard, Vancouver, ISO, and other styles

36

Abou-Hamad, John, Jonathan J. Hodgins, Edward Yakubovich, Barbara C. Vanderhyden, Michele Ardolino, and Luc A. Sabourin. "Sox10-Deficient Drug-Resistant Melanoma Cells Are Refractory to Oncolytic RNA Viruses." Cells 13, no. 1 (2023): 73. http://dx.doi.org/10.3390/cells13010073.

Full text

Abstract:

Targeted therapy resistance frequently develops in melanoma due to intratumor heterogeneity and epigenetic reprogramming. This also typically induces cross-resistance to immunotherapies. Whether this includes additional modes of therapy has not been fully assessed. We show that co-treatments of MAPKi with VSV-based oncolytics do not function in a synergistic fashion; rather, the MAPKis block infection. Melanoma resistance to vemurafenib further perturbs the cells’ ability to be infected by oncolytic viruses. Resistance to vemurafenib can be induced by the loss of SOX10, a common proliferative

APA, Harvard, Vancouver, ISO, and other styles

37

Bradbury, Jane. "Oncolytic viral anti-cancer therapy: a magic bullet?" Lancet 357, no. 9256 (2001): 614. http://dx.doi.org/10.1016/s0140-6736(05)71407-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Gupta, Shishir Kumar, Ravi Kumar Gandham, A. P. Sahoo, and A. K. Tiwari. "Viral genes as oncolytic agents for cancer therapy." Cellular and Molecular Life Sciences 72, no. 6 (2014): 1073–94. http://dx.doi.org/10.1007/s00018-014-1782-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Wojton, Jeffrey, and Balveen Kaur. "Impact of tumor microenvironment on oncolytic viral therapy." Cytokine & Growth Factor Reviews 21, no. 2-3 (2010): 127–34. http://dx.doi.org/10.1016/j.cytogfr.2010.02.014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Tong, Alex W. "Oncolytic viral therapy for human cancer: Challenges revisited." Drug Development Research 66, no. 4 (2005): 260–77. http://dx.doi.org/10.1002/ddr.20058.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Ambegoda-Liyanage, Prathibha, and Sophia R. J. Jang. "Resistance in oncolytic viral therapy for solid tumors." Applied Mathematics and Computation 469 (May 2024): 128546. http://dx.doi.org/10.1016/j.amc.2024.128546.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Sosnovtceva, A. O., N. F. Grinenko, A. V. Lipatova, P. M. Chumakov, and V. P. Chekhonin. "Oncolytic viruses for therapy of malignant glioma." Biomeditsinskaya Khimiya 62, no. 4 (2016): 376–90. http://dx.doi.org/10.18097/pbmc20166204376.

Full text

Abstract:

Effective treatment of malignant brain tumors is still an open problem. Location of tumor in vital areas of the brain significantly limits capasities of surgical treatment. The presence of tumor stem cells resistant to radiation and anticancer drugs in brain tumor complicates use of chemoradiotherapy and causes a high rate of disease recurrence. A technological improvement in bioselection and production of recombinant resulted in creation of viruses with potent oncolytic properties against glial tumors. Recent studies, including clinical trials, showed, that majority of oncolytic viruses are s

APA, Harvard, Vancouver, ISO, and other styles

43

Wang, Joshua L., Kristen M. Scheitler, Nicole M. Wenger, and J. Bradley Elder. "Viral therapies for glioblastoma and high-grade gliomas in adults: a systematic review." Neurosurgical Focus 50, no. 2 (2021): E2. http://dx.doi.org/10.3171/2020.11.focus20854.

Full text

Abstract:

OBJECTIVEHigh-grade gliomas (HGGs) inevitably recur and progress despite resection and standard chemotherapies and radiation. Viral therapies have emerged as a theoretically favorable adjuvant modality that might overcome intrinsic factors of HGGs that confer treatment resistance.METHODSThe authors present the results of systematic searches of the MEDLINE and ClinicalTrials.gov databases that were performed for clinical trials published or registered up to July 15, 2020.RESULTSFifty-one completed clinical trials were identified that made use of a virus-based therapeutic strategy to treat HGG.

APA, Harvard, Vancouver, ISO, and other styles

44

Pathak, Upasana, Ramprasad B. Pal, and Nagesh Malik. "The Viral Knock: Ameliorating Cancer Treatment with Oncolytic Newcastle Disease Virus." Life 13, no. 8 (2023): 1626. http://dx.doi.org/10.3390/life13081626.

Full text

Abstract:

The prospect of cancer treatment has drastically transformed over the last four decades. The side effects caused by the traditional methods of cancer treatment like surgery, chemotherapy, and radiotherapy through the years highlight the prospect for a novel, complementary, and alternative cancer therapy. Oncolytic virotherapy is an evolving treatment modality that utilizes oncolytic viruses (OVs) to selectively attack cancer cells by direct lysis and can also elicit a strong anti-cancer immune response. Newcastle disease virus (NDV) provides a very high safety profile compared to other oncolyt

APA, Harvard, Vancouver, ISO, and other styles

45

Khan, Sumbul, Terri Higgins, Isabella Shimko Lofano, and Payal Agarwal. "Abstract 6551: Exploring oncolytic viral therapy to target osteosarcoma." Cancer Research 85, no. 8_Supplement_1 (2025): 6551. https://doi.org/10.1158/1538-7445.am2025-6551.

Full text

Abstract:

Abstract Osteosarcoma (OS) is a mesenchymal neoplasm. OS makes up approximately 3% of all malignancies in children. The mortality rate has not changed in the last few decades; therefore, the development of advanced cancer therapies is essential. We hypothesize that next-generation conditionally replicative oncolytic virus with an armed anti-PD1 HcAb will lyse the OS cells and initiate the immune response against tumor cells in the tumor microenvironment.The purpose of the study is to evaluate the oncolytic activity and production/ secretion of anti-PD1 Hcab by conditionally replicative Canine

APA, Harvard, Vancouver, ISO, and other styles

46

Kartika, Juspeni, and Legiran. "Stem Cell in Breast Cancer Theraphy." Clinical and Research Journal in Internal Medicine 5, no. 2 (2024): 178–83. http://dx.doi.org/10.21776/ub.crjim.2024.005.02.12.

Full text

Abstract:

There is a lot of research to support that cancer stem cell attract normal stem cell. The tendency of tumor cells to attract stem cells then becomes the basis for the use of stem cells in breast cancer theraphy. When neural stem cell applied as a carrier, it will make the amount, timing, and location of viral oncolytic or drug release can be precisely controlled. Finally, this situation will increase the effectiveness of breast cancer therapy and reduce side effects. This is a brief review about potency of stem cell as breast cancer treatment. This article aim to increased our knowledge about

APA, Harvard, Vancouver, ISO, and other styles

47

Buchatskyi, L. P. "VESICULOVIRUSES AS A TOOL OF BIOTECHNOLOGY." Biotechnologia Acta 16, no. 4 (2023): 22–30. http://dx.doi.org/10.15407/biotech16.04.022.

Full text

Abstract:

Vesiculoviruses are widely used in various fields of biotechnology. This article analyzes the results of published experimental works devoted to the development of oncolytic and recombinant vaccines against emergent viral infections based on vesiculoviruses. The use of genetic engineering methods makes it possible to strengthen their immunogenicity and oncolytic potential. Aim. Analysis and summarization of available information devoted to the development of oncolytic and other vaccines based on vesiculoviruses. Materials and methods. Publications were selected based on the PubMed (https://pub

APA, Harvard, Vancouver, ISO, and other styles

48

Nazarenko, Alina S., Alena O. Shkirdova, Ekaterina A. Orlova, et al. "Viral-Porphyrin Combo: Photodynamic and Oncolytic Viral Therapy for Potent Glioblastoma Treatment." International Journal of Molecular Sciences 25, no. 23 (2024): 12578. http://dx.doi.org/10.3390/ijms252312578.

Full text

Abstract:

Combined viral and photodynamic therapy for oncological diseases has great potential to treat aggressive tumors such as glioblastomas. A conjugate of vesicular stomatitis virus (VSV) with protoporphyrin IX was prepared, and its oncolytic effects were studied and compared to the effects of the individual components. The VSV showed an oncolytic effect on glioblastoma cell lines T98G and LN229 at a virus titer of 105 TCID50/mL. A VSV titer of 104 TCID50/mL was sufficient for neuroblastoma cell death. A study of the effect of VSV in tumor 3D cell modeling found that VSV had a clear viral cytopathi

APA, Harvard, Vancouver, ISO, and other styles

49

Liao, Tianxing, Yu Chen, Lili Guo, et al. "The NP protein of Newcastle disease virus dictates its oncolytic activity by regulating viral mRNA translation efficiency." PLOS Pathogens 20, no. 2 (2024): e1012027. http://dx.doi.org/10.1371/journal.ppat.1012027.

Full text

Abstract:

Newcastle disease virus (NDV) has been extensively studied as a promising oncolytic virus for killing tumor cells in vitro and in vivo in clinical trials. However, the viral components that regulate the oncolytic activity of NDV remain incompletely understood. In this study, we systematically compared the replication ability of different NDV genotypes in various tumor cells and identified NP protein determines the oncolytic activity of NDV. On the one hand, NDV strains with phenylalanine (F) at the 450th amino acid position of the NP protein (450th-F-NP) exhibit a loss of oncolytic activity. T

APA, Harvard, Vancouver, ISO, and other styles

50

Lu, Victor M., Ashish H. Shah, Frederic A. Vallejo, et al. "Clinical trials using oncolytic viral therapy to treat adult glioblastoma: a progress report." Neurosurgical Focus 50, no. 2 (2021): E3. http://dx.doi.org/10.3171/2020.11.focus20860.

Full text

Abstract:

OBJECTIVEAdult glioblastoma (GBM) has proven refractory to decades of innovation. Oncolytic viral therapy represents a novel therapy that uses viral vectors as both a delivery and therapeutic mechanism to target GBM cells. Despite the growing body of basic science data supporting the feasibility of viral therapy to treat GBM, the reporting of clinical trial results is heterogeneous. Correspondingly, the aim of this study was to present a contemporary summary of the progress all clinical trials have made to date.METHODSThe ClinicalTrials.gov database was reviewed in August 2020 for all possible

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!